Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells

Leukemia

Volumn 25, Issue 4, 2011, Pages 588-598

  Masiero, M ^a   Minuzzo, S ^a   Pusceddu, I ^b   Moserle, L ^a   Persano, L ^a   Agnusdei, V ^a   Tosello, V ^c   Basso, G ^a   Amadori, A ^a,b   Indraccolo, S ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

apoptosis; MKP 1; Notch3; tumor dormancy

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; NOTCH3 RECEPTOR; SHORT HAIRPIN RNA; SYNAPTOPHYSIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARCINOGENICITY; CELL SURVIVAL; ENZYME ACTIVATION; ENZYME REGULATION; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 79954441639     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.323     Document Type: Article

References (42)

1. Grabher C, von Boehmer H, Look AT. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer 2006; 6: 347-359.
2. Weng AP, Ferrando AA, Lee W, Morris IV JP, Silverman LB, Sanchez-Irizarry C et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269-271. (Pubitemid 39336870)
3. Matsuoka S, Oike Y, Onoyama I, Iwama A, Arai F, Takubo K et al. Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev 2008; 22: 986-991. (Pubitemid 351544237)
4. Thompson BJ, Buonamici S, Sulis ML, Palomero T, Vilimas T, Basso G et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med 2007; 204: 1825-1835. (Pubitemid 47236320)
5. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 2007; 13: 1203-1210. (Pubitemid 47530629)
6. Dohda T, Maljukova A, Liu L, Heyman M, Grander D, Brodin D et al. Notch signaling induces SKP2 expression and promotes reduction of p27Kip1 in T-cell acute lymphoblastic leukemia cell lines. Exp Cell Res 2007; 313: 3141-3152. (Pubitemid 47161022)
7. Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A et al. NOTCH1 directly regulates c-MYC and activates a feedforward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci USA 2006; 103: 18261-18266. (Pubitemid 44871646)
8. Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 2006; 20: 2096-2109. (Pubitemid 44157460)
9. Aifantis I, Vilimas T, Buonamici S. Notches, NFkappaBs and the making of T cell leukemia. Cell cycle 2007; 6: 403-406. (Pubitemid 46393441)
10. Liu WH, Hsiao HW, Tsou WI, Lai MZ. Notch inhibits apoptosis by direct interference with XIAP ubiquitination and degradation. EMBO J 2007; 26: 1660-1669.
11. Mungamuri SK, Yang X, Thor AD, Somasundaram K. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res 2006; 66: 4715-4724.
12. Bellavia D, Campese AF, Alesse E, Vacca A, Felli MP, Balestri A et al. Constitutive activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 transgenic mice. EMBO J 2000; 19: 3337-3348. (Pubitemid 30428211)
13. Aifantis I, Raetz E, Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol 2008; 8: 380-390. (Pubitemid 351595220)
14. Lee SH, Jeong EG, Yoo NJ, Lee SH. Mutational analysis of NOTCH1, 2, 3 and 4 genes in common solid cancers and acute leukemias. Apmis 2007; 115: 1357-1363.
15. Indraccolo S, Minuzzo S, Masiero M, Pusceddu I, Persano L, Moserle L et al. Cross-talk between tumor and endothelial cells involving the Notch3-Dll4 interaction marks escape from tumor dormancy. Cancer Res 2009; 69: 1314-1323.
16. Vacca A, Felli MP, Palermo R, Di Mario G, Calce A, Di Giovine M et al. Notch3 and pre-TCR interaction unveils distinct NF-kappaB pathways in T-cell development and leukemia. EMBO J 2006; 25: 1000-1008. (Pubitemid 43372114)
17. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007; 7: 834-846. (Pubitemid 350006258)
18. Aguirre Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin andMAPK signaling. J CellBiol 1999; 147: 89-104.
19. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 2003; 63: 1684-1695. (Pubitemid 36373662)
20. Boutros T, Chevet E, Metrakos P. Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol Rev 2008; 60: 261-310.
21. Indraccolo S, Stievano L, Minuzzo S, Tosello V, Esposito G, Piovan E et al. Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment. Proc Natl Acad Sci USA 2006; 103: 4216-4221.
22. Keyaerts M, Verschueren J, Bos TJ, Tchouate-Gainkam LO, Peleman C, Breckpot K et al. Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of D: -luciferin: effect on intensity, time kinetics and repeatability of photon emission. Eur J Nucl Med Mol Imaging 2008; 35: 999-1007.
23. Indraccolo S, Tisato V, Tosello V, Habeler W, Esposito G, Moserle L et al. Interferon-alpha gene therapy by lentiviral vectors contrasts ovarian cancer growth through angiogenesis inhibition. Hum Gene Therapy 2005; 16: 957-970. (Pubitemid 41153865)
24. Indraccolo S, Habeler W, Tisato V, Stievano L, Piovan E, Tosello V et al. Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors. Cancer Res 2002; 62: 6099-6107. (Pubitemid 35244458)
25. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 2007; 117: 3988-4002. (Pubitemid 350224108)
26. Wu JJ, Bennett AM. Essential role for mitogen-activated protein (MAP) kinase phosphatase-1 in stress-responsive MAP kinase and cell survival signaling. J Biol Chem 2005; 280: 16461-16466. (Pubitemid 40616777)
27. Brondello JM, Pouyssegur J, McKenzie FR. Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation. Science 1999; 286: 2514-2517.
28. Kassel O, Sancono A, Kratzschmar J, Kreft B, Stassen M, Cato AC. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J 2001; 20: 7108-7116. (Pubitemid 34062302)
29. Li M, Zhou JY, Ge Y, Matherly LH, Wu GS. The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulation. J Biol Chem 2003; 278: 41059-41068. (Pubitemid 37280929)
30. Lin YW, Yang JL. Cooperation of ERK and SCFSkp2 for MKP-1 destruction provides a positive feedback regulation of proliferating signaling. J Biol Chem 2006; 281: 915-926.
31. Yaglom J, O'Callaghan-Sunol C, Gabai V, Sherman MY. Inactivation of dual-specificity phosphatases is involved in the regulation of extracellular signal-regulated kinases by heat shock and hsp72. Mol Cell Biol 2003; 23: 3813-3824. (Pubitemid 36597461)
32. Chattopadhyay S, Machado-Pinilla R, Manguan-Garcia C, Belda-Iniesta C, Moratilla C, Cejas P et al. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer. Oncogene 2006; 25: 3335-3345. (Pubitemid 43846318)
33. Liu Y, Shepherd EG, Nelin LD. MAPK phosphatasesFregulating the immune response. Nat Rev Immunol 2007; 7: 202-212.
34. Keyse SM. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev 2008; 27: 253-261.
35. Zhang Y, Reynolds JM, Chang SH, Martin-Orozco N, Chung Y, Nurieva RI et al. MKP-1 is necessary for T cell activation and function. J Biol Chem 2009; 284: 30815-30824.
36. Bulavin DV, Fornace Jr AJ. p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res 2004; 92: 95-118. (Pubitemid 39458114)
37. Kennedy NJ, Cellurale C, Davis RJ. A radical role for p38 MAPK in tumor initiation. Cancer Cell 2007; 11: 101-103. (Pubitemid 46209855)
38. Bellavia D, Campese AF, Vacca A, Gulino A, Screpanti I. Notch3, another Notch in T cell development. Semin Immunol 2003; 15: 107-112. (Pubitemid 36390168)
39. Rothenberg EV. Notchless T cell maturation? Nature Immunol 2001; 2: 189-190. (Pubitemid 33705990)
40. Berset T, Hoier EF, Battu G, Canevascini S, Hajnal A. Notch inhibition of RAS signaling through MAP kinase phosphatase LIP-1 during C. elegans vulval development. Science 2001; 291: 1055-1058. (Pubitemid 32157416)
41. Kondoh K, Sunadome K, Nishida E. Notch signaling suppresses p38 MAPK activity via induction of MKP-1 in myogenesis. J Biol Chem 2007; 282: 3058-3065. (Pubitemid 47084350)
42. Sarmento LM, Huang H, Limon A, Gordon W, Fernandes J, Tavares MJ et al. Notch1 modulates timing of G1-S progression by inducing SKP2 transcription and p27 Kip1 degradation. J Exp Med 2005; 202: 157-168. (Pubitemid 41002918)